Can 68Ga PSMA PET/CT be useful in assessment of response to treatment in patients with carcinoma prostate?

Conclusions: 68Ga PSMA PET/CT is a feasible and effective modality for monitoring response to treatment in patients with metastatic disease from prostate cancer post systemic therapy and has a competitive advantage over serum PSA used alone. Discordance between the response on PET/CT based on PET parameters and biochemical response raises the possibility of its true representation of the post-therapy disease burden. It may be used as a guide to planning local therapy in cases with limited disease burden. It is particularly useful in cases with low pre-therapy serum PSA levels. Secondary observations hint its ability to be a predictor of early disease relapse.

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Rangarajan, V., Mhatre, N., Agrawal, A., Shah, S., Purandare, N., Puranik, A., Prakash, G., Bakshi, G., Joshi, A., Prabhash, K., Noronha, V., Pal, M., Murthy, V., Krishnatry, R., Menon, S. Tags: Prostate Diagnosis II Source Type: research